Angle PLC Parsortix shows evidence of CTCs in glioblastoma
August 28 2018 - 2:01AM
RNS Non-Regulatory
TIDMAGL
Angle PLC
28 August 2018
ANGLE plc ("the Company")
PARSORTIX SYSTEM PROVIDES THE FIRST EVIDENCE OF CIRCULATING
TUMOUR CELL CLUSTERS IN GLIOBLASTOMA
Parsortix system detects CTCs in the peripheral blood of brain
cancer patients
Liquid biopsy may provide key information for the treatment of
brain cancer patients where tissue biopsy is not possible
ANGLE plc (AIM:AGL OTCQX:ANPCY), a world-leading liquid biopsy
company, is pleased to announce that its Parsortix(TM) system is
the subject of a further peer-reviewed publication in the British
Journal of Cancer, detailing collaborative research work lead by
Professor Nicola Aceto at the Cancer Metastasis Laboratory,
University of Basel (Basel).
Basel has demonstrated that, using the Parsortix system with a
simple blood test, they can detect circulating tumour cells (CTCs)
in human glioblastoma and that these can be analysed to provide
molecular characterisation of the cancer. Until now, it has been
hypothesised that clusters of CTCs in brain cancers will generally
not pass through the blood-brain barrier. Basel has now shown that,
as well as singular CTCs, clusters of CTCs will pass through the
blood-brain barrier and can be harvested for analysis using the
Parsortix system. Clusters are known to be highly efficient
metastatic precursors and are consequently of particular medical
interest.
The authors state that their work "provides the first evidence
that circulating glioblastoma clusters can overcome the blood-brain
barrier and reach the peripheral circulation".
The publication entitled "Detection of circulating tumour cell
clusters in human glioblastoma" is available here:
https://angleplc.com/library/publications/
In addition, two other recent peer-reviewed publications
involving Parsortix have also been added to the website. These are:
1) Cytometry Part A "The Parsortix(TM) Cell Separation System - A
Versatile Liquid Biopsy Platform" and 2) Journal of Clinical
Pathology "The precious cell block".
ANGLE Founder and Chief Executive, Andrew Newland,
commented:
"The glioblastoma work is a further example of ground breaking
research being undertaken by a Parsortix customer in addition to
ANGLE's own efforts to commercialise the Parsortix system.
University of Basel and their collaborators are working on the
application of this approach for the treatment of glioblastoma
patients and we look forward to reporting further developments in
due course."
For further information ANGLE:
ANGLE plc +44 (0) 1483 343434
Andrew Newland, Chief Executive
Ian Griffiths, Finance Director
finnCap Ltd (NOMAD and Joint Broker)
Corporate Finance - Carl Holmes, Simon Hicks, Max Bullen-Smith
ECM - Alice Lane +44 (0)20 7220 0500
WG Partners (Joint Broker)
Nigel Barnes, Nigel Birks, Andrew Craig, Chris Lee +44 (0) 203 705 9330
FTI Consulting
Simon Conway, Mo Noonan, Stephanie Cuthbert +44 (0) 203 727 1000
Evan Smith, Anne Troy (US) +1 212 850 5612
For Frequently Used Terms, please see the Company's website on
http://www.angleplc.com/the-parsortix-system/glossary/
Notes for editors
About ANGLE plc www.angleplc.com
ANGLE is a world leading liquid biopsy company with sample to
answer solutions. ANGLE's proven patent protected platforms include
an epitope-independent circulating tumor cell (CTC) harvesting
technology and a downstream analysis system for cost effective,
highly multiplexed analysis of nucleic acids and proteins.
ANGLE's cell separation technology is called the Parsortix(TM)
system and it enables a liquid biopsy (simple blood test) to be
used to provide the cells of interest. Parsortix is the subject of
granted patents in Europe, the United States, Canada, India, China,
Japan and Australia and three extensive families of patents are
being progressed worldwide. The system is based on a microfluidic
device that captures live cells based on a combination of their
size and compressibility. The Parsortix system has a CE Mark for
Europe and FDA clearance is in process for the United States.
ANGLE's analysis technology for proteins and nucleic acids of
all types is called Ziplex(R) and is based on a patented flow
through array technology. It provides for highly multiplexed, rapid
and sensitive capture of targets from a wide variety of sample
types. A proprietary chemistry allows for the capture and
amplification of over 100 biomarkers simultaneously in a single
reaction. These technologies can be combined to provide fully
automated, sample to answer results in both centralised laboratory
and point of use cartridge formats. It is ideal for measuring gene
expression and other markers directly from Parsortix harvests.
ANGLE has established formal collaborations with world-class
cancer centres. These Key Opinion Leaders are working to identify
applications with medical utility (clear benefit to patients), and
to secure clinical data that demonstrates that utility in patient
studies. Details are available here
http://www.angleplc.com/the-company/collaborators/
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRAPGURPRUPRGAC
(END) Dow Jones Newswires
August 28, 2018 02:01 ET (06:01 GMT)
Angle (LSE:AGL)
Historical Stock Chart
From Mar 2024 to Apr 2024
Angle (LSE:AGL)
Historical Stock Chart
From Apr 2023 to Apr 2024